Back to results
US 2025/0084060 A1Published application
Prmt5 inhibitors and methods of treatment
OwnerAo Yu, Ho Yin Loinventors
Life of this patent
Estimating the term…
Abstract
The present invention relates to protein arginine N-methyltransferase-5 inhibitors and more specifically to substituted quinazoline-2,4 compounds useful as such agents. These inhibitors are useful as anti-cancer agents.
Claims14
A compound having the following formula
- wherein
- X is C1-C6 alkyl, CO, or a bond,
- Y is, at each occurrence, is independently N, CH, or CR2.
- R1 is H, C1-C6 alkyl, C1-C6 heteroalkyl, phenyl, C3-C7 heterocycle, C3-C7 carbocycle, C5-C6 heteroaromatic, C8-C11 spirocycle, C8-C11 heterospirocycles, amide, alkoxy, or C7-C12 fused or bridged bicyclics or heterobicyclics, optionally substituted at any position with one or more R3
- R2 is H, hydroxy, halo, C1-C6 alkyl halide, C1-C6 alkoxy, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkynyl, C1-C6 heteroalkyl, C1-C6 heteroalkenyl, C1-C6 heteroalkynyl, amino, alkyl amide, alkyl carboxylic acid, pyridyl, methoxy pyridyl, phenyl, fluorophenyl, and cyano, or a pharmaceutically acceptable salt, ester, prodrug, or solvate thereof
- wherein R1 optionally has the formula A1-L1-B1-, where A1 is a first aromatic, heteroaromatic, carbocycle, heterocycle, spirocycle, or bridged or fused combinations thereof, where L1 is a linker selected from alkyl, heteroalkyl, CO, O, N, or S, and where B1 is a second aromatic, heteroaromatic, carbocycle, heterocycle, spirocycle, heterospirocycle, or bridged or fused combinations thereof, wherein B1 is attached to the N of the remainder of the compound
- wherein R3 is selected from H, halo, hydroxy, acyl, —C═OR4, alkyl halide, alkoxy, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, amino, alkyl amide, alkyl carboxylic acid, and cyano, each optionally connected through a C1-C6 linker, and
- wherein R4 is H or a C1-C6 alkyl, C1-C6 heteroalkyl, aryl, or heteroaryl, or a pharmaceuticaly acceptable salt, ester, prodrug, or solvate thereof.
5 more elements
A compound selected from one of the following compounds 1-105, or a pharmaceutically acceptable salt, ester, prodrug, or solvate thereof:
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
102 more elements
A method of treating a cancer comprising administering to a mammalian subject in need thereof one or more compounds according to the following formula:
- wherein
- X is C1-C6 alkyl, CO, or a bond,
- Y is, at each occurrence, is independently N, CH, or CR2.
- R1 is H, C1-C6 alkyl, C1-C6 heteroalkyl, phenyl, C3-C7 heterocycle, C3-C7 carbocycle, C5-C6 heteroaromatic, C8-C11 spirocycle, C8-C11 heterospirocycles, amide, alkoxy, or C7-C12 fused or bridged bicyclics or heterobicyclics, optionally substituted at any position with one or more R3
- R2 is H, hydroxy, halo, C1-C6 alkyl halide, C1-C6 alkoxy, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkynyl, C1-C6 heteroalkyl, C1-C6 heteroalkenyl, C1-C6 heteroalkynyl, amino, alkyl amide, alkyl carboxylic acid, pyridyl, methoxy pyridyl, phenyl, fluorophenyl, and cyano, or a pharmaceutically acceptable salt, ester, prodrug, or solvate thereof
- wherein R1 optionally has the formula A1-L1-B1-, where A1 is a first aromatic, heteroaromatic, carbocycle, heterocycle, spirocycle, or bridged or fused combinations thereof, where L1 is a linker selected from alkyl, heteroalkyl, CO, O, N, or S, and where B1 is a second aromatic, heteroaromatic, carbocycle, heterocycle, spirocycle, heterospirocycle, or bridged or fused combinations thereof, wherein B1 is attached to the N of the remainder of the compound
- wherein R3 is selected from H, halo, hydroxy, acyl, —C═OR4, alkyl halide, alkoxy, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, amino, alkyl amide, alkyl carboxylic acid, and cyano, each optionally connected through a C1-C6 linker, and
- wherein R4 is H or a C1-C6 alkyl, C1-C6 heteroalkyl, aryl, or heteroaryl, or a pharmaceutically acceptable salt, ester, prodrug, or solvate thereof.
5 more elements
Dependencies are inferred from the claim text.